BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31626203)

  • 1. [Morphological and immunohistochemical characteristics of the molecular subtypes of urothelial carcinomas].
    Osmanov YI; Gaibov ZA; Kogan EA; Radenska-Lopovok SG; Tursunov KZ
    Arkh Patol; 2019; 81(5):35-44. PubMed ID: 31626203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative morphological characteristics and immunophenotype of urothelial carcinomas of the renal pelvis and bladder].
    Osmanov YI; Gaibov ZA; Kogan EA; Radenska-Lopovok SG; Tursunov KZ
    Arkh Patol; 2018; 80(5):23-32. PubMed ID: 30335057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations.
    Bang H; Park H; Park S; Choi E; Cho MS; Sung SH; Choi SY; Cho YM; Jeong SU; Ro JY
    Ann Diagn Pathol; 2020 Feb; 44():151433. PubMed ID: 31785538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
    Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
    PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Markers of stem cells and their prognostic values for urothelial carcinomas of the urinary tract].
    Osmanov YI; Kogan EA; Rapoport LM; Teodorovich OV; Gaibov JA
    Urologiia; 2019 Jun; (2):40-49. PubMed ID: 31162900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
    Xiao GQ; Barrett MM; Yang Q; Unger PD
    Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
    Angeloni M; van Doeveren T; Lindner S; Volland P; Schmelmer J; Foersch S; Matek C; Stoehr R; Geppert CI; Heers H; Wach S; Taubert H; Sikic D; Wullich B; van Leenders GJ; Zaburdaev V; Eckstein M; Hartmann A; Boormans JL; Ferrazzi F; Bahlinger V
    J Pathol Clin Res; 2024 Mar; 10(2):e12369. PubMed ID: 38504364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
    Mai KT; Busca A; Belanger EC
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.
    Yorozu T; Sato S; Kimura T; Iwatani K; Onuma H; Yanagisawa T; Miki J; Egawa S; Ikegami M; Takahashi H
    Clin Genitourin Cancer; 2020 Aug; 18(4):e443-e449. PubMed ID: 31983622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
    Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
    Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
    Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
    Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
    Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
    Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical Expression of Cyclin D1, Cytokeratin 20, and Uroplakin III in Proliferative Urinary Bladder Lesions Induced by o-Nitroanisole in Fischer 344/N Rats.
    Willson CJ; Flake GP; Sills RC; Kissling GE; Cesta MF
    Vet Pathol; 2016 May; 53(3):682-90. PubMed ID: 26319780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Uroplakin III, a specific membrane protein of urothelial umbrella cells, as a histological markers for metastatic transitional cell carcinomas].
    Moll R; Laufer J; Wu XR; Sun TT
    Verh Dtsch Ges Pathol; 1993; 77():260-5. PubMed ID: 7511294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
    Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
    Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation.
    Gupta G; Gupta R; Pasricha S; Sharma A; Durga G; Kamboj M; Tripathi R; Mehta A
    Indian J Pathol Microbiol; 2022; 65(4):832-838. PubMed ID: 36308189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.